Table 3.
Distribution frequency of the clinical status and growth arrest-specific 5 (GAS5) rs145204276 genotype frequencies in 430 UCC patients.
| Variable | GAS5 (rs145204276) | |||
|---|---|---|---|---|
| Ins/Ins (%) (n = 191) | Ins/Del + Del/Del (%) (n = 239) | OR (95% CI) | p Value | |
| Stage | ||||
| Non-muscle-invasive tumor | 104 (54.5%) | 131 (54.8%) | 1.000 (reference) | |
| Muscle-invasive tumor | 87 (45.5%) | 108 (45.2%) | 0.986 (0.673–1.444) | 0.940 |
| Tumor T status | ||||
| Ta | 44 (23.0%) | 46 (19.3%) | 1.000 (reference) | |
| T1-T2 | 81 (42.4%) | 116 (48.5%) | 1.370 (0.830–2.262) | 0.218 |
| T3-T4 | 66 (34.6%) | 77 (32.2%) | 1.116 (0.658–1.892) | 0.684 |
| Lymph node status | ||||
| N0 | 166 (86.9%) | 213 (89.1%) | 1.000 (reference) | |
| N1 + N2 | 25 (13.1%) | 26 (10.9%) | 0.811 (0.451–1.455) | 0.481 |
| Metastasis | ||||
| M0 | 186 (97.4%) | 230 (96.2%) | 1.000 (reference) | |
| M1 | 5 (2.6%) | 9 (3.8%) | 1.456 (0.480–4.418) | 0.505 |
| Histopathologic grading | ||||
| Low grade | 23 (12.0%) | 30 (12.6%) | 1.000 (reference) | |
| High grade | 168 (88.0%) | 209 (87.4%) | 0.954 (0.534–1.703) | 0.873 |
The odds ratio (OR) with their 95% confidence intervals were estimated by logistic regression models.